Literature DB >> 315754

Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.

W T Hughes.   

Abstract

Trimethoprim-sulfamethoxazole has been proven effective in the treatment and prevention of Pneumocystis carinii pneumonitis in lower animals and humans. How effective the drug combination is in eradicating P. carinii from the host is not known. The immunosuppressed rat model was used to determine whether or not trimethoprim-sulfamethoxazole effectively eradicated the organism. Animals treated with trimethoprim-sulfamethoxazole for as long as 6 weeks were then placed in individual isolator cages, immunosuppressed with prednisone for 12 weeks, and sacrificed. P. carinii was found in the lungs of at least 90% of the drug-treated as well as untreated control groups. The data indicate that trimethoprim-sulfamethoxazole has a limited rather than a lethal effect on P. carinii and that protection is afforded only during the period of trimethoprim-sulfamethoxazole administration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315754      PMCID: PMC352856          DOI: 10.1128/AAC.16.3.333

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Delayed development of pneumocystis pneumonia following administration of short-term high-dose trimethoprim-sulfamethoxazole.

Authors:  L J Wolff; R L Baehner
Journal:  Am J Dis Child       Date:  1978-05

2.  Recurrent pneumocystis carinii pneumonia following apparent recovery.

Authors:  W T Hughes; W W Johnson
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

3.  Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.

Authors:  W T Hughes; S Feldman; S C Chaudhary; M J Ossi; F Cox; S K Sanyal
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

4.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

Authors:  L L Pifer; W T Hughes; S Stagno; D Woods
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

5.  Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

Authors:  W T Hughes; S Feldman; S K Sanyal
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

6.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

7.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

  7 in total
  17 in total

1.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  Pneumocystis pneumonia.

Authors:  S B Kaye
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-12

Review 3.  Pneumocystis carinii: a misunderstood opportunist.

Authors:  L L Pifer
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

4.  Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

Review 5.  Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients.

Authors:  Adem Ilkay Diken; Ozlem Erçen Diken; Onur Hanedan; Seyhan Yılmaz; Ata Niyazi Ecevit; Emir Erol; Adnan Yalçınkaya
Journal:  World J Transplant       Date:  2016-03-24

6.  Does cyclosporin A adversely affect Pneumocystis carinii infection?

Authors:  R J McGonigle; M Beaman; J Stone; J Young; J Michael; D Adu
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

7.  Interaction of Pneumocystis carinii with host lungs: an ultrastructural study.

Authors:  K Yoneda; P D Walzer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

8.  Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture.

Authors:  L L Pifer; D D Pifer; D R Woods
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

10.  Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; V L Gray; W E Gutteridge; V S Latter; M Pudney
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.